

Stephen E Congly

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3996093/publications.pdf>

Version: 2024-02-01

45
papers

619
citations

623734

14
h-index

642732

23
g-index

46
all docs

46
docs citations

46
times ranked

865
citing authors

#	ARTICLE	IF	CITATIONS
1	Embolization of portosystemic shunts for treatment of medically refractory hepatic encephalopathy. <i>Liver Transplantation</i> , 2016, 22, 723-731.	2.4	59
2	Nationwide estimates and risk factors of hospital readmission in patients with cirrhosis in the United States. <i>Liver International</i> , 2019, 39, 878-884.	3.9	43
3	Epidemiologic Burden and Treatment of Chronic Symptomatic Functional Bowel Disorders in the United States: A Nationwide Analysis. <i>Gastroenterology</i> , 2021, 160, 88-98.e4.	1.3	37
4	Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients. <i>Transplantation</i> , 2016, 100, 1059-1065.	1.0	35
5	Amoebic liver abscess in USA: a population-based study of incidence, temporal trends and mortality. <i>Liver International</i> , 2011, 31, 1191-1198.	3.9	32
6	Impact of the COVID-19 Pandemic on Hospitalizations for Alcoholic Hepatitis or Cirrhosis in Alberta, Canada. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1170-e1179.	4.4	32
7	Sexual Dysfunction and Sex Hormone Abnormalities in Patients With Cirrhosis: Review of Pathogenesis and Management. <i>Hepatology</i> , 2019, 69, 2683-2695.	7.3	31
8	Immunotargeting with CD154 (CD40 Ligand) Enhances DNA Vaccine Responses in Ducks. <i>Vaccine Journal</i> , 2006, 13, 958-965.	3.1	30
9	Portal Vein Thrombosis: Should Anticoagulation Be Used?. <i>Current Gastroenterology Reports</i> , 2013, 15, 306.	2.5	25
10	Epidemiologic and clinical features of chronic hepatitis B virus infection in 8 Canadian provinces: a descriptive study by the Canadian HBV Network. <i>CMAJ Open</i> , 2019, 7, E610-E617.	2.4	22
11	Characterization of hepatitis B virus genotypes and quantitative hepatitis B surface antigen titres in North American tertiary referral liver centres. <i>Liver International</i> , 2013, 33, 1363-1369.	3.9	20
12	Trends in the Economic Burden of Chronic Liver Diseases and Cirrhosis in the United States: 1996-2016. <i>American Journal of Gastroenterology</i> , 2021, 116, 2060-2067.	0.4	19
13	Cost-effectiveness of quantitative hepatitis B virus surface antigen testing in pregnancy in predicting vertical transmission risk. <i>Liver International</i> , 2016, 36, 1604-1610.	3.9	17
14	Cost Effectiveness of Early Insertion of Transjugular Intrahepatic Portosystemic Shunts for Recurrent Ascites. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1503-1510.e3.	4.4	16
15	Interpreting Reported Risks Associated With Use of Proton Pump Inhibitors: Residual Confounding in a 10-Year Analysis of National Ambulatory Data. <i>Gastroenterology</i> , 2020, 158, 780-782.e3.	1.3	16
16	Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis. <i>Scientific Reports</i> , 2021, 11, 17787.	3.3	16
17	Factors Associated With Geographic Disparities in Gastrointestinal Cancer Mortality in the United States. <i>Gastroenterology</i> , 2022, 163, 437-448.e1.	1.3	16
18	Real-world clinical and virological outcomes in a retrospective multiethnic cohort study of 341 untreated and tenofovir disoproxil fumarate-treated chronic hepatitis B pregnant patients in North America. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1707-1716.	3.7	15

#	ARTICLE	IF	CITATIONS
19	Canadian Association of Gastroenterology Position Statement: Use of Cannabis in Gastroenterological and Hepatic Disorders. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, 37-43.	0.3	14
20	The cirrhosis care Alberta (CCAB) protocol: implementing an evidence-based best practice order set for the management of liver cirrhosis - a hybrid type I effectiveness-implementation trial. <i>BMC Health Services Research</i> , 2020, 20, 558.	2.2	14
21	Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting. <i>PLoS ONE</i> , 2021, 16, e0251741.	2.5	14
22	Hepatitis B immunoglobulin for prevention of hepatitis B virus infection and recurrence after liver transplantation. <i>Expert Review of Clinical Immunology</i> , 2011, 7, 429-436.	3.0	11
23	Canadian liver transplant allocation for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 71, 1058-1060.	3.7	10
24	Liver Transplant Tourism. <i>Liver Transplantation</i> , 2020, 26, 276-282.	2.4	9
25	Roadmap to resuming care for liver diseases after coronavirus disease 2019. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 885-892.	2.8	9
26	Variable access to antiviral treatment of chronic hepatitis B in Canada: a descriptive study. <i>CMAJ Open</i> , 2019, 7, E182-E189.	2.4	8
27	Hepatitis B virus testing and linkage to care in a Canadian urban tertiary referral centre: a retrospective cohort study. <i>CMAJ Open</i> , 2017, 5, E431-E436.	2.4	6
28	Assessment of Canadian policies regarding liver transplant candidacy of people who use alcohol, tobacco, cannabis, and opiates. <i>Canadian Liver Journal</i> , 2020, 3, 372-380.	0.9	6
29	Practical management of esophageal varices in the context of SARS-CoV-2 (COVID-19): the Alberta protocol. <i>Canadian Liver Journal</i> , 2020, 3, 300-303.	0.9	6
30	Long-Term Follow-up and Quantitative Hepatitis B Surface Antigen Monitoring in North American Chronic HBV Carriers. <i>Annals of Hepatology</i> , 2018, 17, 232-241.	1.5	5
31	Impact of specialized multidisciplinary care on cirrhosis outcomes and acute care utilization. <i>Canadian Liver Journal</i> , 2021, 4, 38-50.	0.9	5
32	Outcomes and management of viral hepatitis and human immunodeficiency virus co-infection in liver transplantation. <i>World Journal of Gastroenterology</i> , 2014, 20, 414.	3.3	5
33	Canadian regulations and legal ramifications for hepatic encephalopathy: a descriptive analysis. <i>CMAJ Open</i> , 2018, 6, E575-E579.	2.4	3
34	Clinical Course and Treatment Implications of Combination Immune Checkpoint Inhibitor-Mediated Hepatitis: A Multicentre Cohort. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 39-47.	0.3	3
35	Rifaximin for Episodic, Overt Hepatic Encephalopathy: The Data are Catching up to Clinical Practice, but Questions Remain. <i>American Journal of Gastroenterology</i> , 2014, 109, 598.	0.4	2
36	Treatment of acute hepatitis C virus is cost-effective but at what price?. <i>Hepatology</i> , 2018, 67, 1640-1641.	7.3	2

#	ARTICLE	IF	CITATIONS
37	Evaluating the role of transient elastography post chronic hepatitis C treatment to predict hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 73, 1287-1289.	3.7	2
38	Screening for Hepatocellular Carcinoma in Patients with Hepatitis B. <i>Viruses</i> , 2021, 13, 1318.	3.3	2
39	Distinguishing Between Sex and Gender Is Critical for Research in Transplantation. <i>Transplantation</i> , 2020, 104, e57-e57.	1.0	1
40	Assessment of Canadian policies regarding liver transplant candidacy of people who use alcohol, tobacco, cannabis, and opiates. <i>Canadian Liver Journal</i> , 0, , e20200005.	0.9	1
41	Successful Treatment of a Reinfected Liver Graft Because of Receipt of a HCV-Positive Kidney. <i>ACG Case Reports Journal</i> , 2020, 7, e00341.	0.4	0
42	An update from the Canadian Association for the Study of the Liver on the management of liver disease during the COVID-19 pandemic. <i>Canadian Liver Journal</i> , 2020, 3, 309-321.	0.9	0
43	An Incidental Finding of Spontaneous Hepatic Artery Thrombosis in a Healthy Patient. , 2022, 1, .		0
44	Is diabetes a risk factor for malignancy post-transplant in liver transplant recipients?. <i>Annals of Hepatology</i> , 2022, 27, 100703.	1.5	0
45	Extramedullary Myeloma to the Liver Following Bispecific Antigen T-Cell Treatment for Refractory Multiple Myeloma. , 2022, 1, 516.		0